Optimizing the use of biological therapy in patients with inflammatory bowel disease
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimizing the use of biological therapy in patients with inflammatory bowel disease
Authors
Keywords
-
Journal
Gastroenterology Report
Volume 3, Issue 1, Pages 63-68
Publisher
Oxford University Press (OUP)
Online
2015-01-08
DOI
10.1093/gastro/gou087
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
- (2014) Y. Mazor et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
- (2014) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Treatment algorithms in Crohn's – Up, down or something else?
- (2014) Ophélie Antunes et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Have Biologics Changed the Natural History of Crohn's Disease?
- (2014) Michael D. Mandel et al. DIGESTIVE DISEASES
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease
- (2014) Byron P. Vaughn et al. INFLAMMATORY BOWEL DISEASES
- Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: Correlation to clinical and laboratory findings
- (2014) F. Gothe et al. Journal of Crohns & Colitis
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
- (2013) Jean–Frédéric Colombel et al. Clinical Gastroenterology and Hepatology
- Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study
- (2013) Monica Cesarini et al. DIGESTIVE AND LIVER DISEASE
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
- (2013) Laurent Peyrin-Biroulet et al. GUT
- Abdominal Pain in Ulcerative Colitis
- (2013) Matthew D. Coates et al. INFLAMMATORY BOWEL DISEASES
- Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease
- (2013) Sorcha O’Meara et al. INFLAMMATORY BOWEL DISEASES
- UEG Week 2013 Oral Presentations
- (2013) United European Gastroenterology Journal
- Cost Per Responder Associated with Biologic Therapies for Crohn’s Disease, Psoriasis, and Rheumatoid Arthritis
- (2012) Yifei Liu et al. ADVANCES IN THERAPY
- Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis
- (2012) E. Rostholder et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
- (2012) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
- (2012) Kavinderjit S Nanda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn’s disease
- (2012) Ana Carolina Mello Nóbrega et al. BMC GASTROENTEROLOGY
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- PMO-235 A randomised placebo-controlled double-blind study of Octasa®4.8 g/day (800 mg tablets 5-ASA) for the induction of endoscopic remission in patients with active ulcerative colitis
- (2012) B G Feagan et al. GUT
- Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
- (2012) Martin Bortlik et al. Journal of Crohns & Colitis
- Clinical, serological and genetic predictors of inflammatory bowel disease course
- (2012) Laurent Beaugerie WORLD JOURNAL OF GASTROENTEROLOGY
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
- (2011) Adedigbo A. Fasanmade et al. CLINICAL THERAPEUTICS
- Epidemiology and Natural History of Inflammatory Bowel Diseases
- (2011) Jacques Cosnes et al. GASTROENTEROLOGY
- Restricted Heterochromatin Formation Links NFATc2 Repressor Activity With Growth Promotion in Pancreatic Cancer
- (2011) Sandra Baumgart et al. GASTROENTEROLOGY
- Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1
- (2011) N Vande Casteele et al. GUT
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
- (2010) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
- (2009) G. R. LICHTENSTEIN et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Impact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab
- (2009) Alan C. Moss et al. DIGESTIVE DISEASES AND SCIENCES
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Immunological mechanism underlying the immune response to recombinant human protein therapeutics
- (2009) Melody Sauerborn et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now